Company: BDRX
Filing Date: 2025-05-12
Form Type: 424B3
Source: 0001214659-25-007340
Chunk: 3

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-05-12
Form: 424B3
Chunk 3
---
 dollar” each refer to the United States dollar (or units thereof); 
 and                                                                              |

| · | “£,” “pence” and “p” each refer to the British pound sterling 
 (or units thereof).                                           |

On March 27, 2023, following shareholder approval, we effected a one-for-20 reverse
split of our Ordinary Shares and our Ordinary Shares began trading on AIM, a market operated by the London Stock Exchange plc, or AIM,
on a split-adjusted basis as of such date. No fractional shares were issued in connection with the reverse stock split. On March 24, 2023,
our shareholders approved the cancellation of admission of our Ordinary Shares on AIM and this cancellation became effective on April
26, 2023.

Concurrently with the reverse split, and in order to continue meeting The NASDAQ
Stock Market LLC’s, or NASDAQ, minimum 500,000 publicly held shares requirement pursuant to Rule 5550(a)(4), on March 27, 2023 we
effected a ratio change in the number of Ordinary Shares represented by our Depositary Shares from 25 Ordinary Shares per Depositary Share
to five Ordinary Shares per Depositary Share.

On June 14, 2023, we held
our annual general meeting of shareholders, or June AGM, and our shareholders passed resolutions, among other procedural items, to approve
the allotment of, and disapplication of pre-emption rights in respect of, up to 7.0 billion Ordinary Shares, or Shareholder Approval.
On June 14, 2023, we also held a general meeting of shareholders, or June GM, and our shareholders passed resolutions to (x)(i) re-designate
our deferred shares into A Deferred Shares, or the Re-Designation, and (ii) subdivide our Ordinary Shares of £0.02 nominal value
each into one ordinary share of £0.001 nominal value and 19 B Deferred Shares of £0.001 nominal value each, each the Subdivision,
which became effective on June 15, 2023 and (y) adopt new articles of association, or the Articles of Association, which make consequential
amendments to the existing articles of association of the Company to reflect the Re-Designation and the Subdivision, together with certain
other changes to reflect that the Ordinary Shares are no longer admitted to trading on AIM. As is standard for deferred shares, each B
Deferred Share has very limited rights and is